Navigation Links
iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that it has commenced patient recruitment in an open-label, proof-of-concept Phase 1b study of its lead compound ITX-5061 in liver transplant patients with hepatitis C virus infection (HCV).  ITX-5061 represents a first-in-class compound that inhibits entry of the hepatitis C virus into liver cells.

"ITX-5061 possesses a unique mechanism of action that prevents the hepatitis C virus from entering liver cells and has demonstrated potent preclinical antiviral activity against all HCV genotypes.In addition, it has already demonstrated safety in more than 280 subjects," said Jeffrey McKelvy, PhD, MD, President and Chief Executive Officer of iTherX.  "We hope ITX-5061 will significantly improve long-term transplant outcomes."

The primary objective of the Phase 1b clinical trial will be to assess the safety and tolerability of ITX-5061 in liver transplant patients.  The study will also assess HCV viral load for three months after liver transplantation to determine if ITX-5061 has any immediate and/or sustained impact on viral kinetics in treated patients. Approximately 20 patients will be enrolled into one of two cohorts:  one group will receive supportive care only, while the second cohort will also receive ITX-5061 at a150 mg daily dose for seven days.  The trial is being conducted at the University of Birmingham, UK under the direction of David Mutimer, MBBS, MD, FRACP, FRCP, Reader in Hepatology at Birmingham University and Consultant Hepatologist to the Birmingham QE Hospital Liver and Hepatobiliary Unit.

Preclinical studies have shown ITX-5061 to be a potent and selective inhibitor of HCV entry into hepatocytes, capable of preventing virus binding/fusion and cell to cell spread, suggesting ITX-5061  may reduce re-infection rates followi
'/>"/>

SOURCE iTherX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
2. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
3. New Mexico Software Initiates Medical Second Opinion Service via Telemedicine for Remote Consultation Review
4. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
5. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
6. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
7. American Regent Initiates Nationwide Voluntary Recall of Sodium Thiosulfate Injection, USP
8. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
9. Zacks Investment Research Initiates Coverage on Viral Genetics
10. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
11. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014   Foundation ... WuXi PharmaTech (Cayman) Inc. (NYSE: WX ) ... genomic profiling to biopharmaceutical companies conducting clinical trials in ... the terms of the collaboration, Foundation Medicine will license ... Foundation Medicine,s FoundationOne® assay at the WuXi Genome Center ...
(Date:10/20/2014)... 2014  Luoxis Diagnostics, Inc., a subsidiary of ... that its academic collaborators will present several peer-reviewed ... its novel RedoxSYS Diagnostic System, a first-in-class platform ... in response to injury or illness.  A poster ... clinical marker will be presented by Christopher ...
(Date:10/20/2014)... , Oct. 20, 2014  AnaptysBio, Inc., a ... antibodies, today announced the appointment of Marco ... Londei will lead the preclinical and clinical development ... "We are pleased to welcome Dr. Londei to ... , President and Chief Executive Officer of AnaptysBio. ...
Breaking Medicine Technology:Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 2Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 3Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 4Foundation Medicine and WuXi PharmaTech Announce Strategic Collaboration to Offer Best-in-Class Comprehensive Genomic Profiling in China 5Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2
... Workers Ensure Emergency Deliveries are Transported , ... chapter of the American Red Cross are hard at work ... endure that could potentially put Philadelphia,s blood supply at risk. ... up a picket line yesterday when their issues were ignored ...
... , , SALT LAKE CITY, Dec. 4 ... signed a sole-source vendor agreement to provide therapy equipment and ... in Tennessee and Georgia. , "We are pleased to ... Larry K. Beardall, executive vice president of sales and marketing ...
Cached Medicine Technology:Striking Red Cross Workers Raise Public Awareness of Unsafe Working Conditions 2
(Date:10/22/2014)... October 22, 2014 For Dr. Iris Hunter, ... money; it’s an extension of her life’s mission. Her extensive ... as the owner of FirstLight HomeCare, make it clear that ... to me that my work makes a difference in the ... entrepreneurial spirit, so after much research, I felt ready to ...
(Date:10/22/2014)... California (PRWEB) October 22, 2014 Hay House ... Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) written ... of Yoga & Recovery. This book is meant to ... in a life of recovery. , Recovery 2.0 is ... 12 Steps; Recovery 2.0 is a guide for what comes ...
(Date:10/22/2014)... Weight Your Body’s Way , In a world where a ... certainly can be difficult to choose the right weight loss ... doing it the healthy way? Set aside the fads and ... exercise regularly, and choose foods with the most nutritional benefits. ... to exercise more and eat less. Despite the number of ...
(Date:10/22/2014)... Steven Reinberg HealthDay Reporter , ... add weight and length may be showing a genetic propensity ... adults, certain genes have been linked to increased body fat, ... fat and lean muscle, the researchers said. At 1 ... By ages 2 and 3, however, these genes were linked ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Measures taken by ... in Ebola-ravaged Liberia may have limited the spread of ... report. The Firestone Natural Rubber Co. provides health ... residents of nearby densely populated communities. Between Aug. ... suspected Ebola cases among those 80,000 people. That incidence ...
Breaking Medicine News(10 mins):Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:ReductionGuruMD Presents Ways to Improve Your Weight Loss Results 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... refugees in unofficial camps are living in slum conditions redolent ... the Journal of Epidemiology and Community Health. , The research ... Gaza Displacement Centre in Beirut, Lebanon in May 2003. , ... lived in, access to outside air, the presence of mould ...
... release is also available in Spanish . ... expert on nutrition, studied the health benefits of the ... studies on the benefits of olive oil have been ... and Greece (the main olive-oil-producing countries), the incidence of ...
... increase , , THURSDAY, Jan. 17 (HealthDay News) -- The ... three decades, according to a new report released Thursday. ... Jones, senior research associate at the Guttmacher Institute, a ... will be published in the March issue of the ...
... Jan. 17 Cardiva Medical, Inc., a,privately held ... System is pleased to announce the addition of ... Cardiva as Vice President,of Finance and Chief Financial ... Business Development and Marketing., "We are very ...
... Pa., Jan. 16 With Gov. Ed,Rendell refusing to ... Exec. Dir. of the more than 65,000-member Council 13,AFSCME, ... is,mobilizing retiree members to fight back. AFSCME recently sent ... call the governor and to send,provided postcards urging him ...
... SEATTLE, Jan. 16 Hagens Berman Sobol Shapiro has ... ) and,Schering-Plough (NYSE: SGP ), manufacturers of Zetia ... Merck and Schering-Plough,violated state consumer protection laws arising from ... is the combination of Zetia and Zocor, a statin ...
Cached Medicine News:Health News:Palestinian refugees living in 'slum conditions' 2Health News:Consuming extra virgin olive oil helps to combat degenerative diseases such as cancer 2Health News:U.S. Abortion Rate Falls to Lowest Level in Decades 2Health News:U.S. Abortion Rate Falls to Lowest Level in Decades 3Health News:Cardiva Medical, Inc. Appoints Two New Officers: Malcolm Farnsworth as Vice President of Finance and Chief Financial Officer and Tara Zerby as Vice President of Business Development and Marketing 2Health News:AFSCME to Gov. Rendell: Don't Cut Health Benefits for State Retirees! 2Health News:Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia 2Health News:Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia 3
... neurodiagnostic for basic and advanced ... a large 12.1" XGA (1024 ... and the latest in technology ... speed, advanced NCS capabilities, advanced ...
... is a non-invasive and painless method of ... Cadwell Laboratories manufactures two magnetic stimulation devices, ... Stimulator (HSMS). The Hight Speed ... rates up to 25 Hz at full ...
... illuminated hand-held potential vision tester measures retinal ... glaucoma. Potential vision testing requires two ... or RAM (formerly known as the Illuminated ... (clip with a pinhole disc and hinged ...
... MOBEE headboxes are ... Xltek's line of portable ... with a robust new ... latest software, XLTEK's standard ...
Medicine Products: